Published in Curr Cancer Drug Targets on February 01, 2007
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci (2015) 1.41
Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol (2007) 1.23
Evidence for a ferryl intermediate in a heme-based dioxygenase. Proc Natl Acad Sci U S A (2009) 1.13
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother (2012) 1.13
BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta (2008) 1.12
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 1.08
Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther (2013) 1.07
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One (2012) 1.02
Substrate-protein interaction in human tryptophan dioxygenase: the critical role of H76. J Am Chem Soc (2009) 1.02
Update on toll-like receptor-directed therapies for human disease. Ann Rheum Dis (2007) 1.00
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother (2013) 0.98
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther (2011) 0.92
Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis. Clin Exp Immunol (2009) 0.91
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology (2013) 0.88
Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner. Stem Cells Dev (2012) 0.87
Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol (2011) 0.85
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother (2012) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J Innate Immun (2014) 0.83
Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol (2012) 0.82
Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression. J Biol Chem (2015) 0.82
Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol (2008) 0.81
Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 0.81
Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch (2009) 0.80
Oligopeptide-mediated gene transfer into mouse corneal endothelial cells: expression, design optimization, uptake mechanism and nuclear localization. Nucleic Acids Res (2009) 0.80
N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. ACS Med Chem Lett (2015) 0.79
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist (2013) 0.79
Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology (2015) 0.78
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis (2015) 0.77
Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses. Oncoimmunology (2012) 0.77
Dendritic cell cancer vaccines: from the bench to the bedside. Rambam Maimonides Med J (2014) 0.77
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clin Cancer Res (2016) 0.76
Platelet-activating factor mediates endotoxin tolerance by regulating indoleamine 2,3-dioxygenase-dependent expression of the suppressor of cytokine signaling 3. J Biol Chem (2017) 0.75
Enantioselective total syntheses of plectosphaeroic acids B and C. J Org Chem (2013) 0.75
Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator β-glucan in a two-case ex vivo non-small-cell lung cancer study. Cold Spring Harb Mol Case Stud (2016) 0.75
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res (2007) 1.10
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets (2005) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res (2003) 1.00
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun (2005) 0.96
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res (2008) 0.93
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem (2011) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther (2011) 0.89
Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res (2002) 0.89
Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem (2003) 0.89
Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res (2007) 0.89
CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. J Radiat Oncol (2013) 0.88
Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther (2007) 0.86
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res (2012) 0.85
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun (2013) 0.84
Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicol In Vitro (2012) 0.84
Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res (2004) 0.83
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene (2003) 0.83
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther (2005) 0.82
Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res (2010) 0.82
Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene (2003) 0.82
The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol (2013) 0.82
Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther (2004) 0.81
Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One (2009) 0.81
mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther (2007) 0.80
RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol (2010) 0.79
Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol (2009) 0.79
Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci (2011) 0.79
A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro (2012) 0.79
Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther (2011) 0.78
RIN3 is a negative regulator of mast cell responses to SCF. PLoS One (2012) 0.78
Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle (2007) 0.78
1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity (2014) 0.77
Perspectives on emerging trends in cancer research. Cancer Res (2011) 0.76
Specific in situ detection of murine indoleamine 2, 3-dioxygenase. J Cell Biochem (2014) 0.76
Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle (2007) 0.75
Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues. J Cell Biochem (2010) 0.75
Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Res (2016) 0.75
A perspective on cancer as an abortive autoimmune response to altered-self. Cancer Res (2015) 0.75
In their own words: interviews with Cell Cycle. Cell Cycle (2010) 0.75